Accure Therapeutics announced raising €7.6 million from Alta Life Sciences et all.
Accure Therapeutics, a Barcelona, Spain-based phrma company that develops a portfolio of new medicines to address CNS diseases, announced securing a €7.6 million ($8.1M) capital investment round.
The funding was provided by Spanish investors Alta Life Sciences and the Centre for Technological and Industrial Development (CDTI).
Accure Therapeutics, founded in 2020 and led by CEO Laurent Nguyen, develops a drug candidate portfolio in three programs (ACT-01, ACT-02, ACT-03) pursuing innovative targets that focus on four areas: Optic Neuritis, Multiple Sclerosis, Parkinson’s Disease and Epilepsy. The company's initial assets, of which ACT-01 is already ready to go to phase 2 of clinical trials and both ACT-02 and ACT-03 are already in the preclinical study phase, come from two Spanish companies from I + D (Bionure and Iproteos), as well as academic research centers with a solid scientific career in the field of neurobiology. The initial portfolio will serve as a basis for further expansion into the future development of innovative R&D programs for CNS indications.